Glioblastoma multiforme (GBM) is a highly invasive brain tumor with limited therapeutic means and poor prognosis. Recent studies indicate that glioma-initiating cells/glioma stem cells (GICs/GSCs) may be responsible for tumor initiation, infiltration, and recurrence. GICs could aberrantly employ molecular machinery balancing self-renewal and differentiation of embryonic neural precursors. Here, we find that paired related homeobox 1 (PRRX1), a homeodomain transcription factor that was previously reported to control skeletal development, is expressed in cortical neural progenitors and is required for their self-renewal and proper differentiation. Further, PRRX1 is overrepresented in glioma samples and labels GICs. Glioma cells and GICs depleted with PRRX1 could not propagate in vitro or form tumors in the xenograft mouse model. The GIC self-renewal function regulated by PRRX1 is mediated by dopamine D2 receptor (DRD2). PRRX1 directly binds to the DRD2 promoter and transactivates its expression in GICs. Blockage of the DRD2 signaling hampers GIC self-renewal, whereas its overexpression restores the propagating and tumorigenic potential of PRRX1-depleted GICs. Finally, PRRX1 potentiates GICs via DRD2-mediated extracellular signal-related kinase (ERK) and AKT activation. Thus, our study suggests that therapeutic targeting the PRRX1−DRD2−ERK/AKT axis in GICs is a promising strategy for treating GBMs.
Introduction
Glioblastoma (also known as glioblastoma multiforme, GBM) is the most common and aggressive brain tumor in human adults, with highly proliferative and invasive features (Kleihues et al., 1993; Huse and Holland, 2010) . Despite extensive treatment including surgery, radiotherapy, and chemotherapy, the median survival remains around 15 months. A better understanding of GBM biology is urgently needed for designing more effective therapies (Stupp et al., 2005 (Stupp et al., , 2009 . Despite the highly heterogeneous nature of GBMs, recent findings have revealed that a subpopulation of GBM cells, termed as glioma-initiating cells (GICs) or glioma stem cells (GSCs), are able to reconstitute GBMs when intracranially xenografted to immune-compromised mice (Galli et al., 2004; Bao et al., 2006) . When cultured in vitro, these cells are capable of generating free-floating aggregates of cells (neurospheres) and producing a variety of differentiated progenies such as neurons, glia, and vasculature cells (Ignatova et al., 2002; Singh et al., 2003; Wang et al., 2010; Cheng et al., 2013) . GICs are believed to be responsible for many key features of GBMs, such as tumorigenesis, invasiveness, therapy resistance, and post-operational relapse. Recent studies have unveiled that factors defining the properties of embryonic and adult neural stem cells (NSCs) also control the propagation and tumorigenicity of GICs (Ligon et al., 2007; Zhu et al., 2014) . Furthermore, there were studies showing that tumor suppressor inactivation in NSCs and neural progenitor cells (NPCs) can give rise to glioma (Zhu et al., 2005; Zheng et al., 2008; Alcantara Llaguno et al., 2009; Swartling et al., 2012) . Although normal stem cells differ from cancer stem cells in many aspects, stem cell maintenance pathways may represent prime targets to eradicate GICs (Eppert et al., 2011; Guryanova et al., 2011) .
Paired related homeobox 1 (PRRX1), also known as PRX1/ PMX1/PHOX1/MHOX, is a homeodomain transcription factor that is required for stemness maintenance of adult NSCs by associating with the transcription factor SOX2 (Supplementary Figure S1A) (Shimozaki et al., 2013) . Further, PRRX1 promotes epithelial−mesenchymal transition (EMT) in both embryonic organogenesis and tumor metastases (Ocana et al., 2012; Hardin et al., 2014; Guo et al., 2015) . Prrx1 homozygous mutant mice display prominent defects in skeletogenesis, such as loss or malformation of craniofacial and limb structures (Martin et al., 1995; Lu et al., 1999a, b) . Interestingly, a recent study showed that loss of Prrx1 is pivotal for breast cancer cells to revert EMT and simultaneously acquire stem cell properties (Ocana et al., 2012) . In contrast, Prrx1-expressing cells tend to self-renew and expand during chronic pancreatitis; the two isoforms, Prrx1a and Prrx1b, promote migration and invasion, respectively, in pancreatic cancer cells (Reichert et al., 2013) . A recent report also showed that activation of Notch signaling by PRRX1 is associated with the invasiveness of GBM cells (Sugiyama et al., 2015) . In addition, PRRX1 plays essential roles in promoting vascular smooth muscle hyperplasia and migration by inducing expression of smooth muscle α-actin (α-SMA) and a number of adhesion and extracellular proteins (Jones et al., 2001; Yoshida et al., 2004) . Collectively, PRRX1 has contextdependent roles in embryogenesis and tumorigenesis.
In the present study, we explored the putative roles of PRRX1 in regulating self-renewal of NPCs during cortical development of mouse cerebrum and propagation of GICs in glioma tumorigenesis. We found that PRRX1 drives self-renewal and tumorigenicity in GICs by promoting expression of dopamine D2 receptor (DRD2).
Results

Prrx1 is required for self-renewal of cortical NPCs and cortical neurogenesis
In a transcriptome analysis of developing mouse cerebral cortex, Prrx1 was identified as one of the transcription factor (TF) genes that are enriched in the germinal zone, ventricular zone (VZ), and subventricular zone (SVZ) of both embryonic and adult cortex. Since PRRX1 is expressed in adult NSCs and essential for their self-renewal (Shimozaki et al., 2013) , we further examined its expression and roles in cortical neurogenesis of mouse cerebrum. In situ hybridization detected prominent Prrx1 signals in the VZ/SVZ of the embryonic day 12.5 (E12.5), E14.5, and E16.5 dorsal forebrain (cerebral cortex), along with robust signals in the epidermis. Prrx1 was also expressed in the VZ/SVZ of the ventral forebrain, but at a lower level ( Figure 1A) . As the VZ/SVZ are the regions where most NPCs reside, double labeling with NPC biomarker Sox2 was performed to show that Prrx1-expressing cells were largely Sox2-positive (Supplementary Figure S1B) . To study whether Prrx1 is required for self-renewal of cortical NPCs, suspension cultured E11.5 or E12.5 NPCs were transduced with lentivirus expressing scramble or short-hairpin RNAs (shRNAs) against Prrx1. NPCs expressing shRNAs against Prrx1 (shPrrx1) generated much fewer and smaller neurospheres and cellular progenies than control shRNAs (Supplementary Figure S1C) . Consistently, in limiting dilution assays, three shRNAs against Prrx1 (Supplementary Figure S1D) all abolished the potentials of NPCs to form neurospheres ( Figure 1B) . Moreover, in adherent NPC cultures, NPCs infected with shPrrx1#1 produced significantly fewer Sox2+ progenitor cells and more TUJ1+ neurons, which could be largely rescued by overexpressing human PRRX1A or PRRX1B with wobble mutations that are resistant to shPrrx1#1 (Supplementary Figure S1H) .
We next conducted in utero electroporation (IUE) to study the roles of Prrx1 in cell fate determination of cortical NPCs in vivo (IUE at E13.5, analyzed at E16.5). First, there were significantly fewer shPrrx1-transduced cortical cells in the VZ/SVZ compared with scramble controls, suggesting enhanced differentiation of NPCs. Second, the majority of shPrrx1-transduced cortical cells, most of which were cortical pyramidal neurons, failed to migrate radially into the cortical plate (CP) but remained in the intermediate zone (IZ), indicating defective neuronal maturation upon Prrx1 depletion (Supplementary Figure S1E) . Consistently, neurons (TUJ1+) in adherent cultured neurospheres transduced with the shPrrx1 lentivirus have much shorter processes (Supplementary Figure S1I) . Third, Prrx1 depletion resulted in fewer transduced cells in the VZ/SVZ that co-localized with Pax6, a marker labels cortical radial glial progenitor cells (47.3% ± 2.7% in control embryos, 28.3% ± 3.4% in shPrrx1#1, and 31.3% ± 0.9% in shPrrx1#8; Figure 1C) ; whereas more transduced cells in the VZ/ SVZ expressed NeuroD2, a transcription factor that is expressed in committed neuronal progenitors and projection neurons (50.5% ± 2% in controls, 58.3% ± 1.2% in shPrrx1#1, and 64% ± 2.6% in shPrrx1#8; Supplementary Figure S1G ). Fourth, significantly fewer Prrx1-depleted cells could be co-labeled with 5-bromo-2′-deoxyuridine (BrdU, 30 min) (29.3% ± 2.3% in controls, 12.6% ± 1.8% in shPrrx1#1, and 12% ± 1.2% in shPrrx1#8; Figure 1D ), suggesting that Prrx1 is involved in the proliferation of these cells. Finally, these phenotypes could be largely reversed by co-electroporating a shPrrx1#1-resisting PRRX1B cDNA (PRRX1B r ), e.g. −36.6% ± 1.5% for Pax6, −43% ± 4.3% for NeuroD2, and −22.2% ± 2.3% for BrdU ( Figure 1C−E) . Furthermore, when cortical NPCs were electroporated with vectors expressing human PRRX1A (short) or PRRX1B (long), more PRRX1-expressing cells resided in the VZ/ SVZ and co-localized with SOX2+ cortical NPCs, compared with controls (Supplementary Figure S1F) , indicating enhanced selfrenewal of NPCs. Similar to Prrx1 knockdown, most PRRX1-overexpressing cells failed to migrate into the CP but resided in the IZ (Supplementary Figure S1F) , suggesting that optimal dosage of Prrx1 in cortical NPCs is essential for their proper differentiation. In summary, tightly controlled Prrx1 expression is required for cortical NPCs to balance self-renewal and differentiation.
High expression of PRRX1 in gliomas and their GICs
Loss of Prrx1 is involved in colonization and acquisition of stem cell properties of cancer cells (Ocana et al., 2012) , whereas Prrx1-expressing cells are enriched for self-renewal properties in a chronic pancreatitis mouse model (Reichert et al., 2013) . We investigated whether PRRX1 plays a role in maintenance of stemness and tumorigenicity of GICs. We first retrieved Affymetrix expression data of 557 GBM samples and 10 normal controls from The Cancer Genome Atlas (TCGA), and observed that PRRX1 expression was significantly elevated in GBMs (P < 0.001). This trend was more prominent in classical and mesenchymal subtypes Figure 1 Prrx1 maintains stemness of cortical NPCs of embryonic cerebrum. (A) Prrx1 in situ hybridization of coronal sections of mouse embryonic dorsal forebrain (cortex) using digoxigenin-labeled RNA probe. Bottom panels showed boxed area in corresponding upper panels. Arrowheads point to epidermis. Dashed lines demarcate boundaries between VZ/SVZ and IZ. Scale bar, 500 μm (upper) and 50 μm (bottom). (B) E11.5 cortical NPCs were transduced with lentiviruses expressing scramble or Prrx1 shRNAs before plating into 96-well plates for limiting dilution assays. Cultures were maintained until day 10, when the number of wells containing spheres for each cell plating density (number of positive cultures) was recorded, calculated, and plotted using online ELDA analysis program (Hu and Smyth, 2009) . Bottom, representative sphere images in each group. Right, incidences of sphere-forming NSCs and P-values between groups. Scale bar, 25 μm. (C and D) Plasmids expressing the indicated shRNAs were in utero electroporated into E13.5 mouse cortex, and embryos were sacrificed at E16.5. BrdU was injected 30 min before sacrificing. Cryo-sectioned brains were subjected to immunofluorescent stainings of Pax6 (C) and BrdU (D), with transduced cells labeled with ZsGreen. PRRX1B r contains wobble mutations resistant to shPrrx1#1. Scale bar, 50 μm. (E) Percentile of Pax6+, BrdU+, and NeuroD2+ cells in transduced cells in the VZ/SVZ. Histograms represent mean ± SD of cortex from three mouse embryos. LV, lateral ventricle; GE, ganglionic eminence.
of GBMs than in neural and proneural subtypes, suggesting its possible function in promoting invasiveness ( Figure 2A ). Next, we examined the expression of PRRX1 in three normal brains and 31 glioma specimens (5 of WHO grade II, 4 of WHO grade III, and 22 of WHO grade IV). Using Quantitative real-time PCR (qRT-PCR), expression levels of PRRX1 were found to be significantly higher in gliomas than in normal brains ( Figure 2B) . Moreover, GBM patients with top 25% PRRX1 expression levels had significantly shorter median survival time than patients with bottom 25% PRRX1 expression levels: 12.6 months vs. 14.9 months (P = 0.04, Figure 2C ). Next, immunohistochemistry using an antibody that recognizes both PRRX1A and PRRX1B revealed robust signals in all glioma samples ( Figure 2D ). Furthermore, immunofluorescent staining showed that a fraction of PRRX1-labeled glioma cells also expressed SOX2 and CD133 (PROM1), two most widely used biomarkers for GICs ( Figure 2E ). In six glioma samples,~2%−48% of cells expressed PRRX1; 26%−91% of PRRX1+ glioma cells expressed SOX2, whereas 3%−61% SOX2+ cells expressed PRRX1. Similarly, 33%−51% PRRX1+ glioma cells expressed CD133, and 28%−55% CD133+ cells expressed PRRX1 in three glioma samples (Supplementary Figure S2A) . To further support our observation that PRRX1 is preferentially expressed in GICs, we performed triple labeling of PRRX1, SOX2, and SSEA-1/CD15, another surface protein that is also enriched in tumor-propagating
Figure 2 PRRX1 is overrepresented in glioma and labels GICs/GSCs. (A) PRRX1 expression in normal and GBM samples using data retrieved from TCGA Affymetrix dataset. Left, comparison of PRRX1 expression levels between 10 normal and 557 GBM samples (***P < 0.001, Student's t-test); right, comparison of PRRX1 expression levels among GBM subtypes (*P < 0.05, ***P < 0.001, ****P < 0.0001, one-way ANOVA followed by Tukey's multiple-comparisons test). (B) Scattered dot plot showing PRRX1 relative expression in three normal cortex samples and 31 glioma samples. Expression data were presented as mean ± SEM. *P = 0.038, unpaired Student's t-test. (C) Kaplan-Meier survival plot for GBM cases in TCGA Affymetrix dataset. PRRX1 high and PRRX1 low are defined as GBM samples within top and bottom quartiles of PRRX1 expression levels in the TCGA dataset (median survival: 12.6 months in PRRX1 high vs. 14.9 months in PRRX1 low , *P = 0.04). cells (TPCs) of GBMs and medulloblastomas (Read et al., 2009; Son et al., 2009) . A large portion of PRRX1-expressing glioma cells were also positive for SSEA-1/CD15 and SOX2 (Supplementary Figure S2B) . Moreover, cultured GICs ubiquitously expressed PRRX1 and SOX2, the expression level of which declined significantly during serum-induced differentiation ( Figure 4A ). Intriguingly, double-immunofluorescent staining for α-SMA (a marker for vascular smooth muscle cells) or CD31 (a marker for vascular endothelial cells) with PRRX1 showed that some PRRX1-labeled cells were positive for α-SMA or had close proximity to glioma vasculatures (Supplementary Figure S2C) , a reported niche for cancer stem cells (Calabrese et al., 2007) . In summary, despite the lack of a universally accepted GIC marker, the enrichment of PRRX1 in GICs/GSCs is supported by several independent widely used GIC markers, suggesting its potential use as a GIC biomarker.
PRRX1 is required for glioma tumorigenesis
The high expression of PRRX1 in GBM samples prompted us to study whether PRRX1 is required for proliferation and tumorigenicity of glioma cells. We constructed multiple shPRRX1 lentiviruses that can efficiently knock down human PRRX1 expression (Supplementary Figure S3A and B). In U251 and U87MG glioma cells, PRRX1 knockdown glioma cells were much less capable of propagating, as shown in colony formation, soft agar, and MTT assays ( Figure 3A−C) . Notably, knockdown of PRRX1 in HeLa, 293T, SH-SY5Y, and SK-N-SH cells had no effect on cell proliferation, although PRRX1 in the latter two cells were relatively abundant (Supplementary Table S1 ). This indicates that cell propagation promoted by PRRX1 is cell type-specific and that shPRRX1 lentiviruses do not have general cytotoxicity (Supplementary Figure S3C) .
To ask whether PRRX1 maintains tumorigenic potential of glioma cells, we inoculated PRRX1-depleted U251 glioma cells subcutaneously or intracranially into immunocompromised (BALB/c-nu/nu) mice. PRRX1-depleted U251 glioma cells were much less potent in generating subcutaneous tumors than control cells ( Figure 3D and E) . Similarly, while all 6 mice inoculated with control U251 cells expressing a scramble shRNA grew prominent intracranial tumors, mice inovulated with U251 cells expressing PRRX1 shRNA barely produced tumor mass ( Figure 3F , Supplementary Figure S3D and E). Collectively, PRRX1 sustains glioma cell proliferation and tumorigenicity.
PRRX1 is essential for self-renewal of GICs isolated from GBM patients
Although immortalized tumor cells are commonly used to study tumorigenesis, they are unable to reflect key properties of cancer stem cells such as differentiation capabilities and heterogeneity. In the past decade, multiple approaches have been developed to establish GICs including serum-free floating culture similar to neurosphere culture of NPCs, adherent culture on laminin-coated plates, and intracranial xenografts in series (Ignatova et al., 2002; Pollard et al., 2009) . From surgical GBM specimens, we established a few GIC/TPC lines using serum-free floating and adherent cultures, all of which ubiquitously expressed PRRX1 along with SOX2 and NESTIN, two markers for neural stem/progenitor cells ( Figure 4A and B, Supplementary Figure S4A ). During serum-or TGFβ-induced differentiation, the expression levels of PRRX1 and SOX2 declined, whereas the expression of markers for astrocytes (GFAP+) and vascular smooth muscle cells (pericytes, α-SMA+) were induced ( Figure 4A , Supplementary Figure S4B and C). To elucidate roles of PRRX1 in GIC self-renewal, we downregulated PRRX1 expression in patient-derived TPC1115 GICs using two shRNAs, shPRRX1#1 and shPRRX1#2 that target the coding sequence and 3′-untranslated region (3′-UTR) of PRRX1, respectively. In line with findings in glioma cell lines, transduction of both shRNAs dramatically decreased neurosphere and cell numbers in neurosphere cultures. Importantly, the cellular loss caused by shPRRX1#2 could be fully rescued by simultaneous expression of lentiviruses expressing PRRX1A and PRRX1B, alone or both (Supplementary Figure S4D and E). In limiting dilution assays, GICs depleted with PRRX1 were much less capable of forming neurospheres, which could also be rescued by PRRX1A and/or PRRX1B overexpression ( Figure 4C ). Consistently, PRRX1-depleted TPC1115, TPC2-80, TPC0209, and TPC0411 GICs could not selfrenew under adherent conditions ( Figure 4D , Supplementary Figure S4F ). Further, PRRX1-depleted TPC2-80 GICs showed markedly reduced tumorigenic capabilities in intracranial xenografted nude mice ( Figure 4E ). Thus, similar to its role in cortical NPC and glioma cell propagation, PRRX1 is indispensible for self-renewal and tumorigenicity of GICs.
PRRX1 transactivates DRD2 in GICs
Next, we used RNA-seq transcriptome analysis to elucidate the molecular mechanisms used by PPRX1 to promote GIC propagation. We collected PPRX1A/B overexpressing and knockdown GIC cells (TPC1115) at 36 h and 72 h post-transduction, respectively, for RNA extraction followed by RNA-seq transcriptome analysis. As expected, the expression levels of genes essential for cell cycle progression, especially for G1/S transition and DNA replication, were dramatically downregulated in PRRX1 knockdown GICs ( Figure 5A, Supplementary Figure S5A ). To our surprise, the transcripts of DRD2, which encodes DRD2, was significantly induced when PRRX1A or PRRX1B was overexpressed and downregulated when PRRX1 was knocked down in TPC1115 cells ( Figure 5B) . Importantly, such PPRX1 regulation of DRD2 was also found in multiple GIC lines (including TPC2-80, TPC1115, TPC0209, and TPC0411), an immortalized human NPC line (ReNcell CX, Millipore), and three glioma cell lines (A172, T98G, and H4) ( Figure 5C −E, Supplementary Figure S5B−F) . It is worth noting that the changes of DRD2 expression upon PRRX1 knockdown or overexpression in GICs and ReNcell CX NPCs were more drastic than those seen in glioma cells. Manipulating PRRX1 expression in other immortal cell lines, including SK-N-SH, SH-SY5Y, U251, U87MG, HeLa, 293T, HL60, K562, and HEL, did not exert consistent effects on DRD2 expression (Supplementary  Table S1 ). In addition, knocking down or overexpressing PRRX1 in embryonic cortical NPCs and primary glial cells derived from neonatal mouse cortex did not consistently alter Drd2 expression (Supplementary Figure S5G and H, Table S1 ). These results indicate that aberrant transactivation of DRD2 by PRRX1 predominantly occurs in stem-like tumor cells from the brain. To validate the specificity of DRD2 induction by PRRX1, we constructed vectors expressing homeodomain-mutated PRRX1A (PRRX1A-HDm) or PRRX1B (PRRX1B-HDm) proteins, in which three key amino acids (NRR) were replaced with alanines to abolish their transcription activities (Supplementary Figure S6D and E) (Desjobert et al., 2009) . Consistently, the transcriptionally inactive mutants, PRRX1A-HDm and PRRX1B-HDm, failed to induce DRD2 expression in GICs ( Figure 5E ). Furthermore, overexpression of PRRX1A-HDm or PRRX1B-HDm, also reduced the capability of neurosphere formation (Supplementary Figure S7A) , suggesting that the transcriptional regulation activity of PRRX1 is required for its self-renewal function.
To address whether PRRX1 transactivates DRD2 expression by direct binding to the DRD2 promoter, we performed a luciferase reporter assay and chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) experiments. In multiple glioma and immortal cell lines, such as H4, T98G, HeLa, and 293T, overexpression of PRRX1A and PRRX1B significantly elevated luciferase activity driven by the DRD2 promoter ( Figure 5G and H, Supplementary Figure S6A and B). Using serial truncation constructs of DRD2 promoter fragments, we mapped the essential region for DRD2 transactivation by PRRX1 located between −281 and −173 bp upstream to the DRD2 transcription starting site (TSS) ( Figure 5F −H, Supplementary Figure S6B and C). In 293T cells, luciferase activity driven by DNA fragments lacking this key region (D2-PrS2 and D2-PrS3) was significantly lower than that driven by DNA fragments containing this region (D2-PrS and D2-PrS1) either under basal condition or upon PRRX1A/PRRX1B overexpression ( Figure 5F−H) . This was largely the case in H4 and T98G glioma cells (Supplementary Figure S6B and C) , except that D2-PrS2 was also responsive to PRRX1 expression but to a lesser extent in T98G cells (Supplementary Figure S6B) . In addition, PRRX1A-HDm or PRRX1B-HDm was not able to induce luciferase activity driven by the DRD2 promoter ( Figure 5G , two panels on the right). To verify whether PRRX1 binds to the DRD2 promoter region, we overexpressed FLAG-tagged PRRX1A or PRRX1B in TPC1115 GIC cells and performed ChIP-qPCR. TPC1115 cells overexpressing untagged PRRX1A and PRRX1B were used as the control. Consistent with the results obtained from luciferase reporter assays, a fragment of the DRD2 promoter region (−350 to −275) was profoundly enriched in both FLAG-PRRX1A-and FLAG-PRRX1B-precipitated DNAs. As a control, two fragments from the SOX9 promoter region (Reichert et al., 2013) could not be precipitated by FLAG-PRRX1 in GICs ( Figure 5I ), in accordance with unchanged SOX9 mRNA levels upon PRRX1 manipulations in GICs (data not shown). Taken together, PRRX1 is both sufficient and necessary to drive DRD2 expression in certain stem-like cells originating from the brain. FBS-induced differentiation for 5 days, PRRX1 and SOX2 expression levels decreased significantly. Scale bar, 50 μm. (B) Immunofluorescent stainings of PRRX1 in TPC1115 GICs transduced with the indicated lentriviruses (ZsGreen+). Scale bar, 50 μm. (C) TPC1115 GICs were transduced with the indicated lentiviruses before plating into 96-well plates for limiting dilution assays. Cultures were maintained until day 10, when the number of wells containing spheres for each cell plating density (number of positive cultures) was recorded, calculated, and plotted using online ELDA analysis program. Bottom, representative sphere images in each group. Right, incidences of sphere-forming GICs and P-values between groups. Scale bar, 25 μm. (D) Adherent cultured GIC cells (TPC1115, TPC2-80, and TPC0209) were transduced with the indicated shRNAs, and cell numbers were counted every other day. Line graphs represent mean ± SEM (n = 3), and statistical significance was determined by one-way ANOVA followed by Tukey's multiple-comparisons test. Comparisons between cells transduced with scramble and PRRX1 shRNAs, were showed, and no statistical difference was found among shRNAs against PRRX1 (sh#1, sh#2, sh#3, sh#5) (***P < 0.001, ****P < 0.0001). (E) Brain sections stained with hematoxylin and eosin (H&E) showing intracranial xenografts derived from TPC2-80 GICs transduced with the indicated lentiviruses. Scale bar, 1 mm.
DRD2 is overrepresented in GICs and is required for the propagation of GICs
To examine whether DRD2 is overrepresented in GICs, we enriched CD133+ cells from glioma specimens using human CD133 MicroBead Kit (Miltenyi Biotec). qRT-PCR assay showed that DRD2 transcripts, along with SOX2 and PRRX1, were indeed significantly overrepresented in CD133+ cell population from two high-grade glioma samples ( Figure 6A) . Moreover, DRD2-labeled cells in glioma samples were largely PRRX1-and SOX2-positive, further indicating the functional interaction between DRD2 and PRRX1 ( Figure 6B ). In recent shRNA and compound screening studies, DRD2 was reported to mediate mitogenic signaling in leukemic cancer stem cells and glioma cells (Sachlos et al., 2012; Li et al., 2014) . In line with these findings, either knocking down DRD2 in GICs or treating GICs with the dopamine receptor antagonist risperidone or haloperidol drastically inhibited GIC proliferation ( Figure 6C and D, Supplementary Figure S6F) ; the concentrations for risperidone (25 μM) and haloperidol (10 μM) to show effects on GICs were similar to that used on U87MG glioma cell lines (Li et al., 2014) .
PRRX1 relies on DRD2 to sustain propagating and tumorigenic potential of GICs
Then, we asked whether DRD2-mediated mitogenic signaling is responsible for PRRX1-dependent GIC propagation. In GIC neurosphere formation assays and limiting dilution assays, DRD2 overexpression could partially reverse neurosphere and cellular loss upon PRRX1 knockdown, which was independent of the presence of DRD2 agonist quinpirole ( Figure 7A, Supplementary  Figure S7B ). Moreover, forced DRD2 expression partially rescued the decreased BrdU incorporation rate caused by PRRX1 knockdown (10.5% BrdU+ cells in untreated TPC1115 GIC cells, 2.1% (G) Dual-luciferase assays were performed using DNA fragments (D2-PrM and D2-PrS) showed in F. Two panels on the left, vectors expressing PRRX1A, PRRX1B, or DRRF were co-transfected with pGL3-D2-PrM or pGL3-D2-PrS into H4 glioma cells. Two panels on the right, vectors expressing wild-type or homeodomain-mutated (HDm) PRRX1A or PRRX1B were cotransfected with pGL3-D2-PrS into 293T and HeLa cells. (H) Vectors expressing PRRX1A or PRRX1B were co-transfected with truncated DRD2 promoter regions into 293T cells for luciferase assays. (I) ChIP-qPCR assays showing enrichment of corresponding DNA fragments (illustrated in F) precipitated in TPC1115 GICs transduced with FLAG-PRRX1A, FLAG-PRRX1B, or control (untagged PRRX1A and PRRX1B co-expression) lentiviruses. ChIP-qPCR for SOX9 promoter region was also performed. in shPRRX1-expressing cells, and 5.1%−5.6% in rescued cells, Figure 7B ). Lastly, in line with in vitro assays, diminished tumorigenic potential of GIC cells upon PRRX1 depletion could be fully restored by overexpressing DRD2 ( Figure 7C) . Notably, both long (D2L) and short (D2S) isoforms of DRD2 were equally potent to rescue compromised propagating and tumorigenic potential of PRRX1-depleted GICs. In contrast, expressing D2L or D2S was not able to rescue proliferation defects induced by PRRX1 depletion in U251 glioma cells. Similarly, DRD2 overexpression could not restore the compromised self-renewal capabilities of Prrx1-depleted NPCs in both neurosphere and adherent cultures (data not shown). These results are in accordance with the inconsistent DRD2 expression upon PRRX1 manipulation in U251, cortical NPCs, and primary cortical glial cells, and support the notion that PRRX1 maintains cell propagation by inducing DRD2 expression specifically in stem-like tumor cells from the brain (Supplementary Table S1 , Figure S5G and H).
Previous reports suggest that DRD2 signaling mediates neuronal functions, cell proliferation, differentiation, and migration by regulating extracellular signal-related kinase (ERK) and PI3K/ AKT pathways (Luo et al., 1998; Kihara et al., 2002; Kim et al., 2006; Li et al., 2014; Mirones et al., 2014) . Moreover, the activation of ERK and PI3K/AKT signals promotes self-renewal and tumorigenicity of GICs (Soeda et al., 2009; Sunayama et al., 2010) . We reasoned that PRRX1 promotes GIC proliferation via DRD2-mediated ERK and AKT phosphorylation. In supporting this hypothesis, PRRX1 knockdown significantly decreased the level of phosphorylated ERK (p-ERK) and AKT (p-AKT) in TPC1115 GICs, which could be partially rescued by overexpressing the long (D2L) or short (D2S) isoform of DRD2. The levels of phosphorylated ERK could be further enhanced by the addition of quinpirole, without significantly altering the levels of total ERK and AKT ( Figure 7D, Supplementary Figure S7C) . Collectively, PRRX1 transactivates DRD2 expression, hence activating ERK and AKT phosphorylation to maintain propagation and tumorigenicity of GICs ( Figure 7E ).
Discussion
It has been come to attention that in addition to its neurophysiological roles, dopamine receptor signaling is also essential in cell proliferation, as well as neural and systemic inflammation (Luo et al., 1998; Shao et al., 2013; Yan et al., 2015) . Notably, extracranial metastasis of GBMs is extremely rare, which might be due to a unique homing environment in the brain for GICs, probably provided by signals mediated by neurotransmitters including dopamine. In the current study, we revealed that PRRX1, a homeodomain transcription factor, maintains self-renewal and tumorigenic potential of GICs by transactivating the expression of DRD2. Our major new findings are as follows: (i) PRRX1 is highly expressed in cortical NPCs and GICs and is required for their self-renewal; (ii) Overexpressing or knocking down PRRX1 in GICs results in upregulation and downregulation of DRD2, respectively; (iii) PRRX1 directly binds to the DRD2 promoter and transactivates its expression; (iv) Decreasing DRD2 expression or applying dopamine antagonists drastically hampers GIC self-renewal, while re-expression of DRD2 in PRRX1-depleted GIC cells restores their propagating and tumorigenic capabilities; (v) PRRX1 promotes GIC self-renewal, probably via DRD2-mediated ERK and AKT phosphorylation. We would like to point out that although a few stem-like markers, such as SOX2, CD133, and SSEA-1, were used to label GICs in glioma specimens, we largely defined GICs according to their self-renewal, differentiation, and tumorigenic capabilities. Future studies will analyze whether glioma cells with high DRD2 expression have functional GIC properties. It is also worthy exploring whether the PRRX1−DRD2−ERK/AKT axis is used by cancer stem cells of other malignant tumors and has clinical applications. For example, a recent study showed that thioridazine, a dopamine receptor antagonist, selectively targets leukemic stem cells but not normal hematopoietic stem cells (Sachlos et al., 2012) .
PRRX1 is both necessary and sufficient for DRD2 expression in GICs and immortalized human NPCs. However, such transactivating activity is absent or much less prominent in mouse cortical NPCs, primary cortical glial cells, and immortalized cell lines (Supplementary Table S1 ). PRRX1 is expressed in embryonic cortical NPCs and essential for them to balance selfrenewal and differentiation in mice, which is in accordance with previous finding stating that PRRX1 maintains self-renewal of mouse adult NSCs (Shimozaki et al., 2013) . Moreover, type-C NPCs in the adult SVZ highly express dopamine receptors and receive dopamine afferents (Hoglinger et al., 2004) . However, Drd2 knockout mice have normal brain development and unaltered number of NSCs in the adult SVZ (Kippin et al., 2005) . Consistently, DRD2 overexpression could not rescue selfrenewal defects in Prrx1-depleted cortical NPCs (data not shown). These findings reinforce the notion that aberrant transactivation of DRD2 by PRRX1 specifically occurs in stem-like tumor cells.
PRRX1 promotes cell propagation of mouse cortical NPCs and immortalized glioma cells independent of DRD2, suggesting that PRRX1 maintains proliferation of non-GICs through a different mechanism. In addition, it is likely that the pro-survival PI3K/ AKT and MAPK/ERK signals are activated by distinct upstream signals in GICs and non-GICs cells (Wei et al., 2013; Li et al., 2014) , and PRRX1 may play a role in this differential regulation. This hypothesis is supported by our findings that PRRX1 regulates DRD2 expression and DRD2-dependent activation of PI3K/ AKT and MAPK/ERK pathways in GICs, whereas it fails to induce DRD2 expression in most non-GICs. Further studies are needed to identify the molecules that mediate DRD2 activation of the PI3K/AKT and MAPK/ERK cascades in GICs, which would be of great help to design better glioma therapeutic strategies. Furthermore, targeting the PRRX1−DRD2 signaling to limit GIC propagating and tumorigenic capability could be more advantageous than dopamine receptor antagonists to avoid neurological side effects.
In a recent study, two isoforms of Prrx1 seemed to display distinct function properties in carcinogenesis. Prrx1b (the short isoform) was found to promote sphere formation in a pancreatosphere assay, whereas Prrx1a (the long isoform) was more potent in promoting migration (Reichert et al., 2013) . However, in glioma samples and GICs, PRRX1A (short) and PRRX1B (long) are expressed at comparable levels (data not shown), and both of them can transactivate DRD2 expression. Moreover, in tumorisphere assays and adherent cultures, PRRX1A and PRRX1B could indiscriminately reverse decreased self-renewal potential of PRRX1-depleted GICs. Hence, it seems that PRRX1A and PRRX1B are equally potent in maintaining GIC propagation by transactivating DRD2 expression. On the other hand, as GICs were maintained in the presence of EGF and FGF2 mitogens, we could not exclude the possibility that the two isoforms may exert discrete functions in GBM tumorigenesis. We also found that some PRRX1-expressing glioma cells reside in close proximity to tumor vasculatures. It would not be surprising if PRRX1 is also involved in GBM invasiveness, with the two isoforms displaying distinct roles in this aspect (Peterson et al., 2005; Sugiyama et al., 2015) .
Materials and methods
Glioma specimen and brain tissue collection
Glioma surgical specimens were collected in Wuhan Union Hospital and Fujian Medical University Union Hospital in accordance with institution-approved protocols. All patients signed and approved consent forms prior to surgery. Specimens were examined by neuropathologists to verify tumor type and grade. Infant human brain samples were acquired from the Chinese Brain Bank Center (CBBC).
Establishment of GICs
Surgically removed GBM tumors were washed and minced followed by dissociating into single cells using the Papain Dissociation System (Worthington Biochemical). Cells were cultured in low-adhesion plates using serum-free media consisting of DMEM/F12 medium (Life Technologies), insulin (10 μg/ml), N2 and B27 supplements (1×, Life Technologies), human recombinant FGF2 and EGF (20 ng/ml each; Life Technologies), and other supplements to form neurospheres. Alternatively, dissociated GBM cells (1 × 10 6 cells per 10-cm dish) were seeded on plates coated with poly-L-lysine (NPCs) or laminin (GBM cells) using the aforementioned serum-free media (EGF is optional for NPC culture) plus 10 μg/ml insulin and 7.5 mg/ml BSA. For all functional studies, only GIC cells between 4 and 10 passages were used.
In vitro limiting dilution assay
Mouse cortical NPCs or GICs were transduced with lentiviruses. Forty-eight hours later, viable cells were counted and decreasing numbers of cells per well (50, 20, 10, and 1) were seeded into 96-well plates. After 10 days, the number of positive cultures was recorded. Extreme limiting dilution analyses were performed using a web-based software available at http:// bioinf.wehi.edu.au/software/elda/ (Hu and Smyth, 2009 ).
RNA-seq transcriptome analysis
TPC1115 GICs were transduced with lentiviruses expressing PRRX1A, PRRX1B, scramble shRNA, shPRRX1#1, and shPRRX1#2, respectively. Cells for PRRX1A/B expression and PRRX1 knockdown were collected 36 h and 72 h post-transfection, respectively. Library construction and paired-end sequencing were performed in Berry Genomics using Hiseq 2500. Quality control, reads alignment, and gene expression analysis were also carried out in Berry Genomics. Gene ontology (GO) analysis was conducted using the Database for Annotation, Visualization and Integrated Discovery, a web-accessible program (Huang da et al., 2009 ).
More detailed methods are described in Supplementary material.
Supplementary material
Supplementary material is available at Journal of Molecular Cell Biology online.
